Sylman Joanna L, Mitrugno Annachiara, Atallah Michelle, Tormoen Garth W, Shatzel Joseph J, Tassi Yunga Samuel, Wagner Todd H, Leppert John T, Mallick Parag, McCarty Owen J T
VA Palo Alto Health Care System, Palo Alto, CA, United States.
Biomedical Engineering, School of Medicine, Oregon Health & Science University, Portland, OR, United States.
Front Oncol. 2018 Mar 21;8:78. doi: 10.3389/fonc.2018.00078. eCollection 2018.
In this review, we discuss the interaction between cancer and markers of inflammation (such as levels of inflammatory cells and proteins) in the circulation, and the potential benefits of routinely monitoring these markers in peripheral blood measurement assays. Next, we discuss the prognostic value and limitations of using inflammatory markers such as neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios and C-reactive protein measurements. Furthermore, the review discusses the benefits of combining multiple types of measurements and longitudinal tracking to improve staging and prognosis prediction of patients with cancer, and the ability of novel frameworks to leverage this high-dimensional data.
在本综述中，我们讨论了癌症与循环系统中炎症标志物（如炎症细胞和蛋白质水平）之间的相互作用，以及在末梢血检测中常规监测这些标志物的潜在益处。接下来，我们讨论了使用中性粒细胞与淋巴细胞比率、血小板与淋巴细胞比率以及C反应蛋白测量等炎症标志物的预后价值和局限性。此外，本综述还讨论了结合多种测量类型和纵向跟踪以改善癌症患者分期和预后预测的益处，以及新型框架利用这种高维数据的能力。
